What is the difference between dasatinib and imatinib? How do treatment effects differ from side effects?

Dasatinib (Dasatinib) and imatinib (Imatinib) are both tyrosine kinase inhibitors (TKI), mainly used to treat chronic myelogenous leukemia (CML) and certain types of acute lymphoblastic leukemia (ALL), especially those who carry the Philadelphia chromosome. There are certain differences between the two in terms of mechanism of action, indications, therapeutic effects and side effects. They will be introduced and compared separately below.

1. Differences in mechanism of action and indications

Imatinib is the first generationBCR-ABL tyrosine kinase inhibitor and an important breakthrough in the history of CML treatment. It prevents the abnormal proliferation of leukemia cells by selectively inhibiting the activity of BCR-ABL fusion protein. The target of imatinib is relatively concentrated, and it is mainly used for patients with newly treated chronic phase CML and is also used for the treatment of other diseases such as GIST (gastrointestinal stromal tumor).

Dasatinib is a second-generation TKI that has stronger affinity and a broader target spectrum than imatinib. In addition to BCR-ABL, dasatinib can also inhibit SRC family kinases, c-KIT, PDGFR and other tyrosine kinases, so it has advantages in the treatment of imatinib-resistant patients. In particular, dasatinib is often used as an alternative treatment for patients harboring BCR-ABL mutations other than T315I.

2. Differences in treatment effects

In newly treated CML patients, imatinib can achieve high hematological remission and cytogenetic remission rates, and many patients can maintain stable disease for a long time. However, there are still some patients who develop drug resistance or poor tolerance during treatment.

Dasatinib has certain advantages over imatinib in terms of efficacy. Studies have shown that dasatinib is faster at achieving deeper molecular responses (such as MR4.5) and has a shorter time to treatment response. In addition, for patients who are ineffective or intolerant to imatinib, dasatinib is a commonly used second-line treatment drug and is also recommended by some guidelines for treatment-naïve patients.

3. Comparison of side effects

The side effects of imatinib are relatively mild, with common ones including edema (especially eyelids and lower limbs), nausea, musculoskeletal pain, mild liver function abnormalities, etc., which can usually be alleviated through symptomatic treatment and rarely lead to drug discontinuation. It has good long-term safety and is suitable for long-term maintenance treatment.

Although dasatinib is more effective, its side effects are relatively more prominent. The more common ones include pleural effusion (especially more likely to occur in the elderly or patients with underlying cardiopulmonary diseases), dyspnea, thrombocytopenia, neutropenia, etc. In addition, dasatinib may cause pulmonary arterial hypertension (PAH), which is rare but requires close monitoring. Once serious side effects occur, it may be necessary to reduce the dose, temporarily stop the medication, or even change the medication.

4. Clinical Considerations in Medication Selection

When choosing dasatinib or imatinib, doctors will make a decision based on the patient's specific condition, whether there are mutations, previous treatment history, and individual tolerance. For treatment-naïve patients who are sensitive to side effects or prefer a safer regimen, imatinib is usually the first choice; while for patients who are resistant to imatinib or have poor response to treatment, dasatinib is a better alternative. If the patient has underlying lung disease, dasatinib needs to be used with caution to avoid the occurrence of pleural effusion or pulmonary hypertension.

In short, imatinib and dasatinib have their own advantages in the treatment of CML: imatinib is safe and suitable for long-term maintenance; dasatinib is more effective and suitable for drug-resistant or high-risk patients. Clinical assessment should be based on the patient's specific conditions and individualized treatment plans should be developed to achieve the best therapeutic effect while taking into account long-term safety.

Reference materials:https://go.drugbank.com/drugs/DB01254